The hormone relaxin has been shown to cause coronary vasodilation and to prevent ischemia/reperfusion-induced cardiac injury in rodents. This study provides evidence that relaxin, used as an adjunctive drug to coronary reperfusion, reduces the functional, biochemical, and histopathological signs of myocardial injury in an in vivo swine model of heart ischemia/reperfusion, currently used to test cardiotropic drugs for myocardial infarction. Human recombinant relaxin, given at reperfusion at doses of 1.25, 2.5, and 5 μg/kg b.wt. after a 30-min ischemia, caused a dose-related reduction of key markers of myocardial damage (serum myoglobin, CK-MB, troponin T) and cardiomyocyte apoptosis (caspase 3, TUNEL assay), as well as of cardiomyocyte contractile dysfunction (myofibril hypercontraction). Compared with the controls, relaxin also increased the uptake of the viability tracer 201 Thallium and improved ventricular performance (cardiac index). Relaxin likely acts by reducing oxygen free radicalinduced myocardial injury (malondialdehyde, tissue calcium overload) and inflammatory leukocyte recruitment (myeloperoxidase). The present findings show that human relaxin, given as a drug to counteract reperfusion-induced cardiac injury, affords a clear-cut protection to the heart of swine with induced myocardial infarction. The findings also provide background to future clinical trials with relaxin as adjunctive therapy to catheter-based coronary angioplasty in patients with acute myocardial infarction.
effects of relaxin could also be able to counteract the pathophysiological mechanisms of ischemic heart disease. In fact, previous studies in rats and guinea pigs have shown that relaxin causes a potent increase in the coronary flow, which may favor blood supply to the ischemic myocardium through collateral blood vessels (7, 10) . Moreover, relaxin can inhibit circulating platelets and neutrophils (11, 12) , which play a key role in myocardial reperfusion injury (13, 14) , and can decrease adhesiveness of coronary endothelial cells to inflammatory cells by a down-regulation of early-and late-phase endothelial cell adhesion molecules (15) . Of note, studies in rodents subjected to cardiac ischemia and reperfusion have shown that porcine relaxin, given preventatively before induction of ischemia, can reduce myocardial injury (10, 16) and increase survival of the infarcted animals (16) . The above studies highlight a possible role of relaxin, exogenous or endogenous, in the prevention of ischemic heart disease. From the clinicians' point of view, these studies also raise the intriguing question as to whether relaxin, besides a merely preventative agent, is also able to afford cardioprotection when ischemia has already induced its adverse effects on the myocardium; in other words, whether relaxin could also be used as a true drug for acute myocardial infarction.
We designed the present study to test the therapeutic potential of recombinant human relaxin in a swine model of ischemia/reperfusion-induced acute myocardial infarction currently employed to test cardiotropic drugs (17) . This model aims at reproducing the event of a patient undergoing acute myocardial infarction that is admitted to a critical care department and subjected to catheter-based reperfusion. Primary transcutaneous coronary angioplasty (PTCA), either by balloon angioplasty and/or by coronary stenting, is now widely accepted as the treatment of choice for acute myocardial infarction (18) . Now, challenge for the next future is to identify adjunctive drugs that can be associated to PTCA to prevent reperfusion injury, enhance myocardial salvage, and thus preserve left ventricular function (19). Indeed, human relaxin could be a promising candidate as adjunctive drug for myocardial infarction, as it can be produced in bulk amounts by recombinant DNA technology (20) and previous clinical trials for scleroderma have shown its virtual lack of toxicity and adverse side effects even at high doses (21, 22) .
MATERIALS AND METHODS

Surgical induction of acute myocardial infarction
The experimental protocol, designed in compliance with the recommendations of the European Economic Community (86/609/CEE) for the care and use of laboratory animals and with the Good Laboratory Practice, was approved by the animal care committee of the University of Florence, Italy. Male swine, 30-40 kg, were anesthetized by ketamine (0.2 ml/kg b.wt.) intubated orotracheally and ventilated mechanically with O 2 and 1.5% isoflurane Electrocardiogram and arterial blood pressure were monitored throughout the experiments. The animals were subjected to median sternotomy to expose the heart. A Swann-Ganz catheter inserted into the superior vena cava was placed in the pulmonary artery to measure blood pressure and cardiac output by the thermodilution method. Cardiac index, i.e., the cardiac output (ml/min) normalized by the body surface area (cm 2 ), was then calculated to evaluate ventricular performance. Another catheter was inserted through the right atrium and placed in the coronary sinus to collect blood samples and to deliver relaxin or its vehicle (PBS). A third catheter was placed in the left atrium to measure the left ventricular filling pressure. Acute myocardial infarction was induced by a classical ischemia/reperfusion method. Ischemia (30 min.) was obtained by transient ligation of the left anterior descending coronary artery after the 2nd diagonal branch and was followed by reperfusion for further 3 h. Five minutes before reperfusion, lidocaine (0.1 mg/kg b.wt.) was administered to reduce the occurrence of lethal ventricular fibrillation (23) . Blood samples were collected at intervals throughout the experiments and kept at 10°C until needed. At the end of reperfusion, animals were killed by intracardiac KCl injection and myocardial tissue samples, taken from the tissue area 1-2 cm below the coronary ligation, were taken for biochemical and ultrastructural analyses, as detailed below.
The extension of the ventricular area rendered ischemic by the coronary ligation could be easily recognized during the ischemic phase, as it became cyanotic and showed reduced contractility, often leading to paradoxical systolic bulging. However, to better identify its extension and exact location, we performed preliminary experiments (n=4) by clamping the aorta below the right brachiocefalic artery and injecting 20 ml of methilene blue solution into the aortic bulb. In all cases, we observed a sharp, triangular ischemic region starting at the coronary ligation and comprising the whole heart apex ( Fig. 1 ). This information was used for tissue sampling at the end of reperfusion.
Drug treatments
Three groups of animals (each group, n=8) were treated with 3 different doses of recombinant human relaxin (Connetics Co., Palo Alto, CA), 1.25, 2.5, and 5 μg/kg b.wt., corresponding to whole doses of ~50, 100, or 200 μg, respectively. These doses were calculated by comparison with those of porcine relaxin used in the previous studies for the prevention of cardiac ischemiareperfusion injury in rats (16) . Relaxin was dissolved in 20 ml PBS and given at reperfusion as a 1 ml/min infusion through the right atrial catheter. The relaxin plasma levels yielded by this administration protocol were monitored by enzyme-linked immunosorbent assay (ELISA; Immundiagnostik, Bensheim, Germany). Animals receiving the vehicle, PBS, were the positive controls (n=8). Sham-operated swine, which underwent the same surgical procedure but did not undergo coronary ligation, were used as negative controls (n=5).
Measurements of blood and tissue markers of myocardial injury and inflammation
Serum myoglobin, CK-MB, and troponin T were measured by routine ELISA kits, according to the manufacturers' instructions. Values were and normalized as percentages of basal values, assumed as 100%.
Tissue markers of myocardial injury and inflammation were investigated on tissue samples taken at the end of reperfusion. They were minced, homogenized in appropriate solutions, and kept frozen at -80°C until use. Myeloperoxidase (MPO), a marker of inflammatory leukocyte infiltration, and malondialdehyde (MDA), a marker of oxygen free radical-mediated cell damage, were measured spectrophotometrically in myocardial tissue homogenates, as described (16) . Tissue calcium overload, a marker of plasma membrane failure due to peroxidative membrane lipid damage, was measured by atomic absorption spectrometry in the tissue homogenates, as in previous studies (10, 16) . Apoptosis in the cardiac tissue was studied by measuring caspase 3 activity in tissue homogenates by a fluorimetric assay, using Ac-DEDV-AMC (Bachem, Weil am Rhein, Germany) as substrate (24) , as well as by TUNEL assay performed on 6-μm-thick sections of formalin-fixed, paraffin-embedded cardiac tissue specimens, collected at the end of reperfusion, using a Klenow-FragEL TM DNA fragmentation detection kit (Oncogene, San Diego, CA).
Transmission electron microscopy of myocardial tissue
This was performed on tissue samples taken at the end of reperfusion, fixed in 4% cacodylatebuffered glutaraldehyde, post-fixed in 1% phosphate-buffered osmium tetroxide, and embedded in Epon 812 epoxy resin. Ultrathin sections stained with uranyl acetate and lead citrate were examined under a JEM 1010 electron microscope (Jeol, Tokyo, Japan) at 80 kV. In each fragment, two series of six to eight ultrathin sections cut at two different levels (each series put on an electron microscopy grid) were examined and photographed. Cardiomyocyte and microvascular endothelium injury were quantitated from electron micrographs (final magnifications ranging from ×3000 to ×20,000) using a semiquantitative method used previously for similar purposes (16) . The criteria used are reported in Table 1 . Each animal was assigned a separate score for myocyte and endothelial injury. The average values (mean±SEM) of each group were then calculated.
Functional evaluation of myocardial salvage by cardiac single-photon emission computed tomography (SPECT)
To this aim, two additional groups of swine (each group, n=8), subjected to the same surgical procedure of induction of myocardial infarction, treated with vehicle (controls) or with 5 μg/kg b.wt. relaxin, were given 201 Thallium chloride ( 201 TlCl, 3 mCi/111 MBq, Amersham Health, Saluggia, Italy), injected as a bolus in the left atrium 10 min before the end of reperfusion.
201 Tl + is a competitor for K + , thereby it labels viable cardiac cells. Then, the animals were killed and their hearts were removed and immediately transferred to the Nuclear Medicine Unit, where they were subjected to single-photon emission computed tomography (SPECT) to evaluate the volume of the myocardium rendered ischemic and to identify and measure the irreversibly damaged myocardial tissue area. The isolated hearts of the swine given 201 TlCl were analyzed using a Picker Prism 3000 XP and CEqual (Cedars-Emory quantitative analysis) software, using a specific cardiac stress SPECT protocol (25) . The device used allows us to discriminate between the normal myocardium picking up 201 Tl + , the ischemic myocardium showing a defective captation of the tracer (region at risk), and the irreversibly damaged myocardium not picking up the tracer at all (irreversibly injured region). It also allows us to reconstruct a 2-D representation of the whole heart, on which a precise localization and quantitation of the cold, nonviable tissue volume can be obtained. For quantitative evaluation, the values are expressed as percentages of normal ventricular 201 Tl captation, assessed as 0% defect (25) . This radiotracer-based method was chosen because it is very sensitive and, being used for diagnostic purposes, it is more familiar to clinicians than the classical nitro-blue tetrazolium-based methods often used to evaluate the size of the infarcted region in experimental animals.
Statistical analysis
The reported data are expressed as the mean ± SEM of the reported number of animals per experimental group. Unless otherwise specified, statistical comparison of differences between the groups was performed using either two-way ANOVA for two variable analysis or one-way 
RESULTS
In this study, relaxin was given for 20 min as a 1 ml/min continuous infusion, starting at reperfusion, to recreate the clinical event of a patient subjected to PTCA and adjunctive therapy in the same surgical session. We tested three increasing doses, 1.25, 2.5, and 5 μg/kg b.wt. Administration of relaxin at the higher doses, e.g., 2.5 and 5 μg b.wt., caused a marked, statistically significant reduction of the main serum markers of myocardial cell damage, namely myoglobin, CK-MB and troponinT, which rose markedly in the control animals given the vehicle alone ( Fig. 2A-C) .
Compared with the vehicle-treated controls, relaxin reduced in a dose-related fashion the tissue parameters of inflammatory leukocyte recruitment, such as MPO (Fig. 3A) and of oxygen free radical-mediated cardiomyocyte injury, such as MDA (Fig. 3B ) and tissue calcium overload (Fig.  3C) . Relaxin also reduced the occurrence of apoptosis in cardiomyocytes, as shown by caspase 3 and TUNEL assay (Fig. 4A, B) . Finally, relaxin, at the doses of 2.5 and 5 μg/kg b.wt., decreased the ultrastructural signs of cardiomyocyte damage ( Fig. 5 ; Table 2 ). In fact, in the vehicle-treated animals, most cardiomyocytes showed cytoplasmic edema, hypercontraction of myofibrils, shrinkage of the plasma membrane, and mitochondrial swelling; in some cases, plasma membrane rupture and nuclear karyolysis were observed. Blood capillaries were usually narrowed and the endothelial cells often showed swelling of cytoplasmic matrix and mitochondria and reduction of pinocytosis vesicles. None of these alterations can be observed upon relaxin treatment, in which cardiomyocytes had almost normal features, apart from moderate attenuation of sarcomeric Z and M lines and sporadic cytoplasmic and mitochondrial swelling, and blood capillaries were normal or even larger than those in the sham-operated swine.
All the above effects of relaxin resulted in an overall protection of the ischemic and reperfused myocardium. As shown by SPECT analysis (Fig. 6) , relaxin (5 μg/kg b.wt.) caused a slight, not statistically significant reduction of the ischemic myocardium showing a defective captation of the viability tracer 201 Tl + , corresponding to the area at risk (44±3.1% in the vehicle-treated swine vs. 39.2%±2.2 in the relaxin-treated swine; Student's t-test: P > 0.05), and a striking reduction of the irreversibly injured myocardial tissue that did not pick up the tracer at all (52.3%±2.6 in the vehicle-treated swine vs. 32.1%±6.2 in the relaxin-treated swine; Student's t-test: P<0.05). Functionally, the relaxin-induced myocardial salvage improved the contractile performance of the heart, as indicated by the long-lasting, stable increase in cardiac index observed upon 5 μg/kg b.w. relaxin (Fig. 7) . However, no significant changes in the trend of other hemodynamic parameters were observed between the relaxin-treated and control animals ( Table 3 ). The plasma levels of human relaxin at different times from infusion of the noted doses in the right atrium are reported in Fig. 8 .
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DISCUSSION
The present study shows that recombinant human relaxin, given as a drug to counteract reperfusion-induced adverse effects in a swine model of acute myocardial infarction, affords a clear-cut protection to the heart as compared with the vehicle-treated controls. In fact, relaxin, administered at reperfusion, causes a reduction of the release of myoglobin, CK-MB, and troponin T into the blood, the classical myocardium-specific proteins currently used to monitor heart injury in infarcted patients, as well as a decrease in the assayed tissue markers of cardiomyocyte apoptosis (caspase 3, TUNEL assay) and in the histopathological signs of cardiomyocyte injury and contractile dysfunction (myofibril hypercontraction). Relaxin also reduces the extension of the irreversibly injured myocardial tissue that did not pick up the viability tracer 201 Tl + . In the meantime, relaxin can sustain the contractile performance of the heart by preventing the decrease in cardiac output that usually occurs in the vehicle-treated swine. The relaxin-induced cardioprotection appears to involve a reduction of oxygen free radical-mediated damage, as suggested by the observed decrease of tissue MDA and calcium overload, likely due to the marked reduction of the recruitment of inflammatory leukocytes (MPO) within the reperfused myocardium. The mechanism of action of relaxin likely relies on an early protection at the level of coronary vessels. In fact, at reperfusion, relaxin could counteract the endothelium-mediated initiation of microcirculatory failure and inflammation, thereby decreasing no-reflow phenomenon and inflammatory myocardial damage. However, the possibility that relaxin could also induce cardiomyocytes to become resistant to reperfusioninduced injury should not be ruled out. At present, clear-cut evidence for specific relaxin receptor expression has been given for atrial but not ventricular cardiomyocytes (5, 6) . Recently, however, a glucocorticoid-like, plasma membrane receptor-independent action of relaxin has been described (26) : this could account for a direct protective effect of relaxin on ventricular cardiomyocytes.
Taken together, the results of this study highlight the therapeutic potential of human relaxin, given as an adjunctive drug to catheter-based reperfusion, to reduce reperfusion injury and enhance heart salvage in acute myocardial infarction, and provides background to future clinical trials. They also provide a useful indication of the relaxin dose that could be used in clinical studies: in fact, 5 μg/kg b.wt. afforded the best myocardial protection in our swine model. Based on the current findings, relaxin appears more promising than other drugs, which have been previously used to reduce ischemia-reperfusion injury, such as antioxidants. These drugs raised enthusiastic expectations when applied to cellular systems but gave rise to conflicting results and little or no concrete benefit when used to relieve heart damage and dysfunction by myocardial infarction, either in animal models or in clinical practice (27) . At variance with antioxidants, relaxin could exert a much broader spectrum of protective actions, which include the reduction of inflammatory leukocyte and platelet response (11, 12, 15, 16) , the inhibition of the release of proinflammatory and arrhythmogenic mediators by mast cells (28) , and the dilatation of coronary blood vessels (7, 10) that could potentiate the direct and collateral circulation to the infarction area and thereby remove harmful substances generated locally by inflammation, reperfusion biochemistry, and cell demise. Relaxin could also show advantages over adenosine, which is currently under clinical investigation for acute myocardial infarction (29) . In fact, adenosine A 1 receptor agonists have been found to cause the heart to become resistant to ischemia (30) , but receptor activation should precede ischemia to afford protection (31) . Hence, A 1 receptor agonists should be maximally effective when administered preventatively before ischemia, whereas the present study shows that relaxin can also exert cardioprotection when given at reperfusion, thus offering very good chances as an adjunctive drug for PTCA.
The current study also shows that, with the noted administration regimen, the protection afforded by relaxin is exerted at low plasma levels (180 to 679 pg/ml with 5 μg/kg b.wt. relaxin; see also Fig. 7) , which are within the physiological range in humans (32, 33) . This finding further supports the hypothesis that endogenous relaxin could be a major physiologic agent involved in the natural protection against cardiovascular disease of women during fertile life (34) . In fact, clinical and epidemiological studies have shown that the incidence of ischemic heart disease in women is very low until ovulation occurs but increases sharply as that in age-matched men upon menopause or oral contraceptive assumption (35) , along with the cessation of ovarian activity and, hence, of luteal secretion of relaxin. Relaxin attains the highest effects at the highest dose (5 µg/kg b.wt.). Significance of differences with I-R: *P < 0.05; **P < 0.01; ***P < 0.001. 201 Tl + and blunts the severity of the defect as compared with the vehicle-treated swine undergoing myocardial infarction (I-R, ischemia-reperfusion). The location and degree of the damaged myocardium can be identified on the 2D images of the ventricular territories supplied by the different coronary arteries: LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; RCA, right coronary artery. The gray/black colored areas in the "extent of defect" 2D images correspond to the region at risk, while the black areas in the "severity of defect" 2D images corresponds to the irreversibly damaged region. 
